Granules India Limited — Investor Meet, 30-01-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Financial Performance: Granules India reported Q3 revenue of ₹1,137.7 crore, down 2% year-over-year but up 18% sequentially. Gross margins improved to 61.7%, a rise of 474 basis points from the previous year, driven by higher-margin finished dosage sales. However, EBITDA declined to ₹230.3 crore, representing a margin of 20.2%, down from 21.7% in Q3 FY24, impacted by increased costs related to US FDA compliance, including air freight and remediation expenses. R&D expenditure was ₹56.8 crore, up from ₹46.8 crore a year prior.

Future Outlook and Growth Drivers: Management emphasized robust growth prospects, underscoring a diversified growth strategy not solely reliant on new product approvals. Key drivers include launches from the US GPI site, growth in large volume products, and ongoing development at the greenfield facility in Genome Valley. The ADHD segment is highlighted as a future growth area, with multiple products in the pipeline.

Order Book and Operational Updates: The Gagillapur facility faced scrutiny from the US FDA, with 90% of remediation actions completed. The plant contributes 60-65% of total revenues, with operational restorations expected to continue as compliance measures take effect.

Analyst Q&A Insights (Detailed): Analysts inquired about revenue growth forecasts and margin recovery, with management indicating that the CAGR is expected to be over 20% in the long term despite recent challenges. Analysts noted a significant upswing in European sales, attributed to prior quarter fluctuations, and management indicated solid prospects for ongoing launches.

Market or Regulatory Updates: The FDA's ongoing engagement is crucial following the OAI classification. Management is optimistic but cautious regarding potential inspection timelines, indicating it could take several quarters.

Strategic Focus Areas: There is a clear focus on R&D and product development across key therapeutic areas, notably ADHD and oncology. Emphasis on improving quality compliance and operational efficiency has fueled potential future market competitiveness.

Investor Insight: Financial health appears stable, reinforced by proactive measures to address regulatory challenges as operations recover. With diversified growth strategies supporting a long-term vision, maintaining exposure to Granules India may be prudent amid anticipated market corrections and recovery efforts.